1. IRINOTECAN FOR CHILDREN WITH RELAPSED SOLID TUMORS
- Author
-
Yoshiaki Tsuchida, Atsushi Manabe, Akira Shimada, Masahito Tsurusawa, Tohru Sugimoto, Keisei Kawa, Hideo Mugishima, Toshiji Shitara, Jun Ichi Mimaya, Ryoji Hanada, and Tadashi Matsunaga
- Subjects
Oncology ,Leiomyosarcoma ,medicine.medical_specialty ,business.industry ,Hematology ,Undifferentiated sarcoma ,medicine.disease ,body regions ,Irinotecan ,Internal medicine ,Partial response ,Primitive neuroectodermal tumor ,Neuroblastoma ,Pediatrics, Perinatology and Child Health ,medicine ,business ,Rhabdomyosarcoma ,neoplasms ,medicine.drug ,Tumor marker - Abstract
Irinotecan is expected to become a new drug for childhood solid tumors. Sixteen children with relapsed solid tumors received irinotecan 180 mg/m2/day for 3 consecutive days, repeated once after 25 days off. Their original tumors were neuroblastoma in 7, rhabdomyosarcoma in 3, nephroblastoma and undifferentiated sarcoma in 2 each, and primitive neuroectodermal tumor and leiomyosarcoma in 1 each. The average age at trials was 6 years. Partial response was achieved in 5 (31.3%) (neuro-blastoma, rhabdomyosarcoma, nephroblastoma, undifferentiated sarcoma, and leiomyosarcoma), and decrease in tumor marker in the other 2. Irinotecan appears promising, and could become included in the first-line treatment.
- Published
- 2006